secwatch.observer — SEC 8-K summary
======================================

Issuer:     Allarity Therapeutics, Inc. (ALLR)
CIK:        0001860657
Form:       8-K
Filed at:   2026-02-19T23:59:59+00:00
Accession:  0001213900-26-018161
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Allarity Therapeutics doses first patients in VA-funded Phase 2 trial of stenoparib + temozolomide for relapsed SCLC
--------------------------------------------------------------------------------

- First patients dosed with stenoparib and temozolomide in Phase 2 trial for relapsed small cell lung cancer (SCLC).
- Trial fully funded by U.S. Department of Veterans Affairs, enrolling at 11 VA medical centers nationwide.
- Stenoparib is a dual PARP and WNT pathway inhibitor; prior PARP inhibitors limited by hematologic toxicity.
- CEO cites fast enrollment and high unmet need; ~60-70% of SCLC patients present with extensive-stage disease.
- Stenoparib crosses blood-brain barrier, relevant for SCLC brain metastases.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1860657/000121390026018161/0001213900-26-018161-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1860657/000121390026018161/ea0277546-8k_allarity.htm
  HTML page:      https://secwatch.observer/filing/0001213900-26-018161

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer